Benzoates

"Benzoates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure.

Descriptor ID	D001565
MeSH Number(s)	D02.241.223.100 D02.455.426.559.389.127
Concept/Terms	Benzoates Benzoates Benzoate Benzoate Benzoic Acids Benzoic Acids Acids, Benzoic

Below are MeSH descriptors whose meaning is more general than "Benzoates".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Carbocyclic [D02.241.223]
Benzoates [D02.241.223.100]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Benzoates [D02.455.426.559.389.127]

Below are MeSH descriptors whose meaning is more specific than "Benzoates".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Benzoates" by people in this website by year, and whether "Benzoates" was a major or minor topic of these publications.

Bar chart showing 17 publications over 10 distinct years, with a maximum of 3 publications in 2005 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	2	1	3
2007	1	0	1
2010	1	0	1
2012	2	0	2
2017	1	0	1
2018	0	1	1
2019	1	1	2
2020	3	0	3
2021	1	1	2
2023	0	1	1

Below are the most recent publications written about "Benzoates" by people in Profiles.

Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mond?sert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023 Jul 08; 402(10396):118-128.

View in: PubMed
Shiuey EJ, Mehran NA, Ustaoglu M, Zhang Q, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Lee D. The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes. Graefes Arch Clin Exp Ophthalmol. 2022 Mar; 260(3):967-974.

View in: PubMed
Syed ZA, Rapuano CJ. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease. Curr Opin Ophthalmol. 2021 May 01; 32(3):268-274.

View in: PubMed
Rapuano PB, Levin AV, Price JM, Myers JS, Lee D, Shukla AG. Early Experience with Netarsudil in Pediatric Patients: A Retrospective Case Series. Ophthalmol Glaucoma. 2021 Mar-Apr; 4(2):232-234.

View in: PubMed
Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, Sheng H, Lewis RA, Heah T, Kopczynski CC. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma. 2020 10; 29(10):878-884.

View in: PubMed
Lin MM, Moster SJ, Zheng CX, Anderson-Qui?ones CD, Katz LJ, Pro MJ, Myers JS, Moster MR, Lee D. Netarsudil's Effect in Eyes with a History of Selective Laser Trabeculoplasty. Ophthalmol Glaucoma. 2020 Jul - Aug; 3(4):306-308.

View in: PubMed
Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2020 01; 34(1):72-88.

View in: PubMed
Sinha S, Lee D, Kolomeyer NN, Myers JS, Razeghinejad R. Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2020 Jan; 21(1):39-45.

View in: PubMed
Soni C, Schell SL, Fasnacht MJ, Chodisetti SB, Rahman ZS. Crucial role of Mer tyrosine kinase in the maintenance of SIGN-R1+ marginal zone macrophages. Immunol Cell Biol. 2018 03; 96(3):298-315.

View in: PubMed
Albrecht D, Ellis D, Canafax DM, Combs D, Druzgala P, Milner PG, Midei MG. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. Thromb Haemost. 2017 04 03; 117(4):706-717.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement